MK
Therapeutic Areas
MabTics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MT-101 | Therapeutic angiogenesis, tumor vessel normalization, diabetic retinopathy, AMD, sepsis | Preclinical |
| MT-103 | Wet age‑related macular degeneration | Preclinical |
| MT-201 | Anti‑thromboinflammatory indication for vascular inflammation and thrombosis | Preclinical |
| MT-40x | Tumor‑targeting antibodies for solid tumors | Preclinical |